Aveo Oncology Inc., of Cambridge, Mass., said the first patient has been dosed in the phase I/II Aveo-sponsored TiNivo trial evaluating tivozanib in combination with New York-based Bristol-Myers Squibb Co.'s anti-PD-1 therapy, Opdivo (nivolumab), in advanced renal cell carcinoma. Tivozanib is an oral, once-daily, vascular endothelial growth factor tyrosine kinase inhibitor.